Characterization of IncRNA Profiles of Plasma-Derived Exosomes From Type 1 Diabetes Mellitus

Haipeng Pang, Wenqi Fan, Xiajie Shi, Jiaqi Li, Yimeng Wang, Shuoming Luo, Jian Lin, Gan Huang, Xia Li, Zhiguo Xie* and Zhiguang Zhou*

National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology (Central South University), Ministry of Education, and Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China

Backgrounds: Exosomes contain several types of transcripts, including long non-coding RNAs (lncRNAs), and have been shown to exert important effects in human diseases. However, the roles of exosomal lncRNAs in type 1 diabetes mellitus (T1DM) have not been well investigated. In the present study, we characterized the plasma-derived exosomal lncRNAs expression profiles of T1DM and predict their potential function in the pathogenesis of T1DM.

Material and Methods: Exosomal IncRNA expression profiles were detected by Illumina Hiseq platform (T1DM subjects N=10; age-, sex- matched Control subjects N=10). Six exosomal IncRNAs were selected to validate their expression level by using quantitative real-time PCR (qRT-PCR) (T1DM subjects N=30; age-, sex- matched Control subjects N=30). Bioinformatics analysis approaches were carried out to explore the potential biological function of differentially expressed IncRNAs.

Results: A total of 162 differentially expressed exosomal IncRNAs were identified in T1DM patients compared with control subjects, among which 77 up-regulated and 85 down-regulated. The expression level of the selected six IncRNAs didn’t show significant difference in the following qRT-PCR analysis. Gene Ontology analysis enriched terms such as activation of phospholipase D activity, neuronal cell body membrane, and calcium sensitive guanylate cyclase activator activity for cis-acting genes of lncRNAs, and metal ion binding for trans-acting genes. The most enriched Kyoto Encyclopedia of Genes and Genomes pathways for the lncRNAs were associated with oxidative phosphorylation and Parkinson's disease for cis-acting genes, and pathways in cancer as well as focal adhesion for trans-acting genes.

Conclusions: This study characterized the IncRNA profiles of plasma-derived exosomes from T1DM for the first time and these results highlighted the potential role of exosomal IncRNAs in T1DM pathogenesis. A better understanding of exosomal IncRNA profiling will provide novel insights into its molecular mechanisms.

Keywords: type 1 diabetes mellitus, exosomes, long non-coding RNA, plasma-derived, bioinformatics analysis
INTRODUCTION

Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by absolute insulin deficiency and resultant hyperglycemia (1, 2). The incidence and prevalence of T1DM are increasing worldwide and more than 463 million people are affected (3, 4). This disease is incurable at present and patients with T1DM have to rely on lifelong insulin administration. Besides, the high prevalence of diabetic complications, such as retinopathy, nephropathy, as well as neuropathy, severely influence the life quality of T1DM patients and impose a considerable financial burden. The pathogenesis of T1DM is extremely complex and multiple factors, including genetic backgrounds, environmental triggers, and behavioral changes, may contribute to the onset and development of T1DM (5–7). An improved understanding of T1DM pathophysiology will render early identification and intervenve of T1DM.

Growing evidence has suggested that a small extracellular vesicle (EV), namely exosome, plays an important role in multiple pathogenic processes, including T1DM (8). Exosomes, which can be released by virtually all cell types, are significant mediators of intercellular communication and interorgan crosstalk through transferring bioactive molecules, including proteins, lipids, and RNAs between cells (9, 10). Moreover, the content of exosomes is strictly regulated in response to all kinds of endogenous or exogenous stimulations, thus reflecting the biological events or disease conditions (11). Therefore, a better understanding of exosomes may provide a valuable target for disease diagnosis and treatment.

Long non-coding RNAs (lncRNAs), a sub-class of non-coding RNA family, have emerged as crucial regulators in multiple pathophysiological conditions (12). LncRNAs are more than 200 nucleotides in length and take part in the regulation of various cellular and biological processes, such as gene silencing, histone modifications and DNA methylation (13, 14). Accumulating evidence has highlighted the role of lncRNAs in pancreatic islets and development of T1DM (15–18). However, the research about the exosomal lncRNA is relatively lacking, especially in T1DM. Here, we investigated the plasma-derived exosomal lncRNA expression profiles in patients with T1DM and explored their biological function. This present work provided a novel insight into the pathogenesis of T1DM and laid a foundation for using exosomal lncRNAs as biomarkers and therapeutic targets for T1DM.

MATERIALS AND METHODS

Study Subjects

Patients with T1DM attending the Diabetes Clinic at the Second Xiangya Hospital were recruited. The inclusion criteria of case group were as follows: (1) fulfilling the WHO diagnostic criteria for diabetes (1999); (2) acute onset and insulin dependency within 6 months after diagnosis; (3) positive for at least one following islet autoantibodies: GADA (glutamic acid decarboxylase antibody), IA-2A (protein tyrosine phosphatase antibody), or ZnTA8 (zinc transporter 8 antibody); (4) diabetes duration less than 5 years. Exclusion criteria included pregnancy, combined with other autoimmune diseases, malignant tumors, or a recent cardiovascular event. Non-diabetic subjects without autoimmune diseases, cancers, or family history of diabetes were recruited as health control. This case-control study was approved by the Ethics Committee of the Second Xiangya Hospital and all the research methods were conducted in accordance with the ethical guidelines of the Declaration of Helsinki. All the participants or their guardians indicated that they fully understand the research goals and procedures, and written informed consent was obtained. A total of 10 cases and 10 controls were included in the discovery phase. There was no significant difference in age (P=0.97) and sex (P=0.36) between two groups (Table 1). Besides, we used a new cohort (T1DM subjects N=30; age-, sex- matched Control subjects N=30) for the following qRT-PCR analysis.

Isolation of Plasma

Peripheral blood was collected in the EDTA blood tubes from each participant and plasma was separated by centrifugation at 3000 g for 15 min at 4°C. The plasma samples were stored at -80°C before use.

Isolation of Exosome

Size exclusion chromatography methods were adopted to isolate exosomes. In brief, 1 mL of 0.8 μm filtered plasma was 1.5-fold diluted with phosphate-buffered saline (PBS) and the further purification was made by using Exosupur® columns (Echobiotech, China). Next, we eluted the samples with 0.1M PBS and collected about 2 mL elute fractions. The collected fractions were then concentrated to 200 μL by 100 kDa molecular weight cut-off Amicon® Ultra spin filters (Merck, Germany). All procedures were operated according to the manufacture’s institutions.

| Characteristic | T1DM (n=10) | Control (n=10) | P value |
|---------------|-------------|----------------|---------|
| Sex (male/female) | 3/7 | 5/5 | 0.36 |
| Age (year) | 25.20 ± 7.24 | 25.10 ± 2.96 | 0.97 |
| BMI (kg/m2) | 21.26 ± 2.71 | 20.40 ± 2.24 | 0.47 |
| Duration (months) | 25.40 ± 14.94 | – | – |
| FPG (mmol/L) | 7.79 ± 3.32 | – | – |
| HbA1c % | 8.01 ± 2.20 | – | – |

BMI, body mass index; FPG, fasting plasma glucose; HbA1c, Hemoglobin A1c.
Transmission Electron Microscopy (TEM)
We put 10 µL purified exosome on a copper mesh and the sample was incubated at room temperature for 1 min. The exosome was negatively stained with uranyl acetate solution for 1 min after washing with sterile distilled water. After dried for 2 min under incandescent light, the exosome was examined under a TEM (H-7650, Hitachi Ltd., Tokyo, Japan).

Nanoparticle Tracking Analysis (NTA)
The size distribution and quality of isolated particle (concentrations between 1x10^7/mL and 1x10^9/mL) were determined by the ZetaView PMX 110 (Particle Metrix, Meerbusch, Germany), which equipped with 405 nm laser. A 60 second video was taken with a frame rate of 30 frames/second. The, the particle movement was analyzed by NTA software (ZetaView 8.02.28).

Western Blot Analysis (WB)
The exosome supernatant was denatured in 5 x sodium dodecyl sulfate (SDS) buffer and subjected to WB analysis (10% SDS-polyacrylamide gel electrophoresis; 50 µg protein/lane) using rabbit polyclonal antibody CD63, TSG101, Alix and calnexin. The proteins were visualized on the Tanon4600 Automatic chemiluminescence image analysis system (Tanon, Shanghai, China). The identification of exosome, including TEM, NTA, and WB analysis, was entrusted the company (Echo Biotech Co., Ltd, Beijing, P. R. China).

Total RNA Isolation
The miRNeasy Serum/Plasma Advanced Kit (Qiagen, cat. No. 217204) was used to extract and purify the exosomal RNA in compliance with the kit instruction. The concentration and purity of RNA were evaluated using the RNA Nano 6000 Assay Kit of the Agilent Bioanalyzer 2100 System (Agilent Technologies, CA, USA).

Library Preparation and Sequencing
The extracted RNA was used as input material for sequencing libraries using the SMARTer Stranded Total RNA-Seq Kit (Takara Bio USA, Inc.) according to manufacturer’s recommendations. Index codes were added to attribute sequences to each sample. At last, library quality was evaluated on the Agilent Bioanalyzer 21000 and qPCR. The clustering of the index-coded samples was performed on acBot Cluster Generation System using TruSeq PE Cluster Kitv3-cBot-HS (Illumina, San Diego, CA, USA). After cluster generation, the library preparations were sequenced on an Illumina Hiseq platform and paired-end reads were generated.

LncRNA Analysis
The transcriptome was assembled using the Stringtie and Scripture based on the reads mapped to the reference genome. The assembled transcripts were annotated using the Cuffcompare program from the Cufflinks package. The unknown transcripts were used to screen for putative lncRNAs. Four computational approaches including CPC, CNCI, Pfam, and CPAT were combined to elect ncRNA candidates from presumed protein-coding RNAs in the unknown transcripts. Presumed protein-coding RNAs were filtered out using exon number threshold and a minimum length. Transcripts having more than two exons and with lengths more than 200 nt were selected as lncRNA candidates and further screened using CPC, CNCI, Pfam, and CPAT that have the power to distinguish the protein-coding genes from the non-coding genes. As well as the different types of lncRNAs include long intergenic lncRNA (lincRNA), intronic lncRNA, anti-sense lncRNA were selected using cuff compare. Stringtie was used to calculate FPKMs of lncRNAs in each sample. Gene FPKMs (fragments per kilo-base of exon per million fragments) were computed by summing the FPKMs of transcripts in each gene group. The lncRNA sequencing and lncRNA analysis were entrusted the company (Echo Biotech Co., Ltd, Beijing, P. R. China).

GO and KEGG Pathway Enrichment Analysis
Gene Ontology (GO) enrichment analysis of the differentially expressed lncRNAs was implemented by the topoGO R packages. We used KOBAS (19) software to test the statistical enrichment of differential expression genes in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (http://www.genome.jp/kegg/).

Quantitative Real-Time PCR (qRT-PCR) Assay
The total RNA from exosomes was extracted using miRNeasy Serum/Plasma Advanced Kit (Qiagen, cat. No. 217204) according to the manufacturer’s protocol. The total RNA was then reverse transcribed to synthesize cDNA using PrimeScript™ RT reagent Kit (Perfect Real Time) (TAKARA, RR037A). The abundance of target gene expression was detected by TaqMan® probe using qRT-PCR. 2 µL of cDNA was used as the template for each PCR reaction. The GAPDH was selected as the internal reference gene. The sequence of primers and probes were shown as Table 2.

Statistical Analysis
We used SPSS software version 20.0 to perform the statistical analysis. The data were presented as mean ± SD (standard deviation). Differential expression analysis of lncRNAs between two groups was performed using the Mann Whitney U test with cutoff FPKM > 5, P-value < 0.05 and Fold change > 1.5. The comparisons of the relative expression level of candidate lncRNAs in qRT-PCR were analyzed by the unpaired t-test. A P-value less than 0.05 was considered as statistically significant.

RESULTS
Characterization of Exosome
We used TEM and NTA to evaluate the morphology and sizes distribution of isolated exosome. As shown by Figure 1, the isolated particles were oval and cup-shaped with diameter range between 30 nm to 200 nm (median, 91.7 nm). WB analysis indicated that the presence of exosomal positive protein markers Alix, Tsg101, and CD63, and the absence of Calnexin, the negative
protein marker for exosome. All these results suggested that the isolated exosomes were well-prepared and with good purity.

An Overview of the RNA Sequencing Results
The procedures of lncRNA sequencing and bioinformatics analysis were summarized in Figure 2. A total of 20 samples, including 10 patients and 10 healthy controls were constructed and analyzed. The percentage of Q30 base was at least 91.94%. A total of 40065 lncRNAs, including 33453 known lncRNAs and 6612 novel lncRNAs were generated. Among these identified lncRNAs, lincRNAs accounted for the largest proportion (69.1%), followed by intronic lncRNAs (15.5%), sense lncRNAs (8.6%), and antisense lncRNAs (6.8%). Then, we predicted the target genes of lncRNA. On the one hand, it is predicted that the adjacent genes within 100 kb were its cis-acting gene because lncRNA could regulate the expression of neighboring genes. On the other hand, the trans-acting genes of the lncRNA were predicted by analyzing the expression correlation between lncRNA and corresponding mRNA. The genes with absolute Pearson correlation coefficient greater than 0.9 and \( P \)-value less than 0.01 were taken as the trans-acting genes of the lncRNA.

| LncRNA      | Symbol | Primer Sequence (5'-3') |
|-------------|--------|------------------------|
| ENST00000533796 | TALDO1-209 | F-GATGCTAACCACAAACCACG R-AAATCTGCTTGTGATCC P-CCGGAAAGCTGGGCGGTCAC |
| ENST00000472614 | GNB1-207 | F-GAGGGCTCTGAGAATAATT R-TGTCCTCTCAGTCTGAC P-AGGAAATTGGAACAGTAGTCCTGCT |
| ENST00000525207 | SF3B2-204 | F-CCTGAAAGAGACCGC R-CTCGATCTCAGGGGGTCAC P-CCAGACAGAAGCCCTTCTAAG |
| ENST00000495420 | ANP32A-208 | F-AGGCCTTAAAGTCCATACCGG R-TTCATTCCAAGCCTAAAGCG P-AGCGCTCCAGAAGCTGG |
| ENST00000488260 | EIF1B-204 | F-CGCGCAAGGCACTGGTGT R-ATCACAGTACCATTACAGGCAAA P-ATCCAGCAACGGAGCA |
| ENST00000505090 | CANX-210 | F-TTCAAGCGAGGGCTTTGTG R-CCTGCATCTCCTGTGGTCCT P-CCCGTGCTGCTGATTACGTC |

TABLE 2 | Primer list. F- refers to the forward sequence, R- refers to the reverse sequence, and P- refers to the probe sequence.

FIGURE 1 | Identification of exosomes. The transmission electron microscopy images of exosomes (A). The size distribution of exosomes analyzed by nanoparticle tracking analysis (B). Validation of marker proteins and negative protein of exosomes (C).

FIGURE 2 | An overview of the RNA sequencing results.
Differentially Expressed Exosomal lncRNAs

Based on the plasma-derived exosomal lncRNA expression profiles, differentially expressed lncRNAs were distinguished between T1DM patients and control subjects. Hierarchical clustering analysis was performed to cluster lncRNAs according to their expression level (Figure 3A). As shown by volcano diagram (Figure 3B) and MA plot (Figure 3C), total of 162 differentially expressed lncRNAs were identified, in which 77 up-regulated and 85 down-regulated (Table 3). These results indicated that plasma-derived exosomal lncRNA expression profiles were distinguishable between T1DM patients and control subjects.

Functional Analysis of Exosomal lncRNAs

To explore the potential biological function of 162 differentially expressed lncRNAs, GO enrichment analysis and the KEGG pathway analysis were employed. The lncRNAs exert biological effects by acting as cis- or trans- regulators (20, 21). We summarized the significantly enriched GO terms of cis-acting genes of differentially expressed lncRNAs regarding to the biological process (BP), cellular component (CC), and molecular function (MF), respectively (Figure 4A). For BP, the term with the most genes and with the highest enrichment score was the activation of phospholipase D activity (GO:0031584) (Figure 4B). For CC, the term with the most genes was the extracellular exosome (GO:0070062) and with the highest score was neuronal cell body membrane (GO:0032809) (Figure 4C). In addition, for MF the terms DNA binding transcription factor activity (GO:0003700) and protein binding (GO:0005515) were associated with most genes, and the most enriched term was calcium sensitive guanylate cyclase activator activity (GO:0008048) (Figure 4D). We also summarized the GO terms of trans-acting genes (Figure 5A). For BP, the term with the most genes was the positive regulation of transcription from RNA polymerase II promoter (GO:0045944) (Figure 5B). For CC, the term cytosol (GO:0005829) was correlated to most genes (Figure 5C). For MF, the term with protein binding (GO:0005515) was most genes, and metal ion binding (GO:0046872) was most significantly enriched term (Figure 5D). Besides, the enriched pathways of target genes of lncRNA were analyzed by KEGG. For cis-acting genes, the most significantly enriched terms were involved in oxidative phosphorylation (ko00190) and Parkinson’s disease (ko05012) (Figure 6A). For trans-acting genes, the terms pathways in cancer (ko05200) and focal adhesion (ko04510) were related to most genes (Figure 6B). We also performed the disease annotation of identified lncRNAs through sequence alignment with LncRNADisease database. The results showed some lncRNAs were associated with autoimmune diseases, including dermatomyositis and polymyositis. LncRNA can be precursor molecule of miRNA. We also detected the lncRNAs which serve as precursor of miRNA through comparing and predicting the miRNA sequence in miRbase database.
FIGURE 3 | Plasma-derived exosomal lncRNA profiles of case and control group. A heatmap (A), volcano diagram (B), and MA plot (C) of the 162 differentially expressed exosomal lncRNAs in T1DM and control subjects. G1: control group; G2: case group.

TABLE 3 | The detailed information of the differentially expressed exosomal lncRNAs.

| ID | Symbol | P-value     | log2FC     | Regulated |
|----|--------|-------------|------------|-----------|
| ENST00000533796 | TALDO1-209 | 6.24E-06 | -6.22261 | down |
| ENST00000547703 | MYL6-208 | 7.84E-06 | -7.97936 | down |
| ENST00000472614 | GNB1-207 | 1.28E-05 | -5.81213 | down |
| ENST00000525207 | SF3B2-204 | 6.42E-05 | 5.004214 | up |
| ENST00000514674 | CCT5-212 | 9.56E-05 | 4.352669 | up |
| ENST00000514918 | NSA2-203 | 0.0013006 | -4.66882 | down |
| ENST00000515015 | IK-208 | 0.00016215 | 5.635708 | up |
| ENST00000438115 | NDUFS7-204 | 0.000199895 | -5.98882 | down |
| ENST00000495692 | RPL36A-208 | 0.00012962 | -4.83713 | down |
| ENST00000620389 | SRSF3-207 | 0.000245929 | -5.60659 | down |
| ENST00000495420 | ANP32A-208 | 0.000265961 | -4.70741 | down |
| ENST00000585223 | DDX5-233 | 0.000385727 | 3.60407 | up |
| ENST00000587642 | WBP2-207 | 0.000387307 | 4.236054 | up |
| ENST00000566031 | NDUFBI1-203 | 0.00054778 | 4.086463 | up |
| ENST00000472568 | ADD3-207 | 0.00059455 | -3.97259 | down |
| ENST00000531008 | RPS13-207 | 0.000641612 | 4.050101 | up |
| ENST00000573505 | ALDH9A2-210 | 0.00070788 | -4.38782 | down |
| ENST00000550184 | MYL6-216 | 0.00078691 | -4.29668 | down |
| ENST000004864800 | ARPC1B-218 | 0.000864268 | -5.89173 | down |
| ENST00000461203 | RPS24-207 | 0.000998187 | 3.280526 | up |
| ENST00000492519 | PABPC4-217 | 0.001059294 | 3.758606 | up |
| ENST00000488260 | EIF1B-204 | 0.001073793 | -4.21143 | down |
| ENST000005861048 | PPIB-203 | 0.001105467 | -4.49263 | down |
| ENST00000489109 | ANXA1-206 | 0.001150385 | -4.69253 | down |

(Continued)
| ID       | Symbol      | P-value   | log2FC  | Regulated |
|----------|-------------|-----------|---------|-----------|
| ENST00000502548 | RACK1-202 | 0.00119424 | -3.65467 | down      |
| ENST00000526990 | EHBP1L1-202 | 0.001204172 | -4.95234 | down      |
| ENST00000472260 | AP2M1-218 | 0.001238868 | 4.07962  | up        |
| ENST00000498038 | HLA-DPB1-217 | 0.001253537 | -3.81907 | down      |
| ENST00000496323 | SPTBN1-202 | 0.001289333 | 4.64114  | up        |
| ENST00000489120 | HLA-DPB1-213 | 0.001305199 | -4.60675 | down      |
| ENST00000525256 | C11orf58-206 | 0.001317929 | 2.814152 | up        |
| ENST00000465744 | RPL36A-206 | 0.001324547 | 4.23729  | up        |
| ENST00000548002 | ATP5SF-208 | 0.001325547 | -3.90611 | down      |
| ENST00000556167 | PSMA6-212  | 0.001325547 | 4.10496  | up        |
| ENST00000515592 | IK-209     | 0.001325547 | -3.4285  | down      |
| ENST00000470287 | FUBP1-205  | 0.001325547 | -5.51764 | down      |
| ENST00000462527 | EIF3A-202   | 0.001325547 | -3.97697 | down      |
| ENST00000515592 | IK-209     | 0.001325547 | -3.4285  | down      |
| ENST00000645908 | RPL5-210    | 0.001325547 | -3.1769  | down      |
| ENST00000529348 | ZBTB44-208  | 0.001325547 | 4.84402  | up        |
| ENST00000498038 | HLA-DPB1-217 | 0.001325547 | -4.22744 | down      |
| ENST00000581745 | RPL19-206   | 0.001325547 | 2.899701 | up        |
| ENST000005578430 | SRSF1-202  | 0.001325547 | -5.57807 | down      |
| ENST00000486032 | OOPS3-208   | 0.001325547 | -3.74238 | down      |
| ENST00000522843 | SDCBP-210   | 0.001325547 | 3.96216  | up        |
| ENST00000466598 | AP2M1-214   | 0.001325547 | 3.528153 | up        |
| ENST00000417088 | RPS28-201   | 0.001325547 | -2.86162 | down      |
| ENST00000645950 | CD99-213    | 0.001325547 | 4.194786 | up        |
| ENST00000520146 | RPL2-203    | 0.001325547 | 2.53549  | up        |
| ENST00000520146 | RPL2-203    | 0.001325547 | 2.53549  | up        |
| ENST00000521046 | RPSA-210    | 0.001325547 | -2.94875 | down      |
| ENST00000529348 | RPL5-210    | 0.001325547 | -3.84491 | down      |
| ENST00000558774 | NUMB-226    | 0.001325547 | 5.53631  | up        |
| ENST00000493790 | EPS15-209   | 0.001325547 | -4.22744 | down      |
| ENST00000494573 | LDHA-211    | 0.001325547 | 3.462046 | up        |
| ENST00000598706 | RAB11B-203  | 0.001325547 | 3.324837 | up        |
| ENST00000525252 | RPL8-203    | 0.001325547 | 3.528153 | up        |
| ENST00000388545 | TPM3-213    | 0.001325547 | 3.442714 | up        |
| ENST00000514842 | RPL9-210    | 0.001325547 | -2.82285 | down      |
| ENST00000489939 | RP17A-207   | 0.001325547 | -3.77403 | down      |
| ENST00000598273 | SELENOW-206 | 0.001325547 | -3.84968 | down      |
| ENST00000460085 | ATP6V1E1-205 | 0.001325547 | 3.098422 | up        |
| ENST00000482404 | LAMTOR5P-202 | 0.001325547 | -4.04501 | down      |
| ENST00000517545 | PCMI-202    | 0.001325547 | -3.51861 | down      |
| ENST00000512682 | AMD1-207    | 0.001325547 | 4.406964 | up        |
| ENST00000471419 | NONO-209    | 0.001325547 | -3.24716 | down      |
| ENST00000565143 | PKM-214     | 0.001325547 | 3.411681 | up        |
| ENST00000488122 | RPLP1-204   | 0.001325547 | -2.21776 | down      |
| ENST00000561798 | UQCRCC2-203 | 0.001325547 | -3.13688 | down      |
| ENST00000557552 | HBG1-203    | 0.001325547 | -3.20313 | down      |
| ENST00000557552 | HBG1-203    | 0.001325547 | -3.20313 | down      |
| ENST00000489732 | NAMPT-212   | 0.001325547 | 2.846161 | up        |
| ENST00000499293 | MSTRG.2552909,33 | 0.001325547 | 4.127691 | up        |
| ENST00000591551 | ZNF224-208  | 0.001325547 | -3.06762 | down      |
| ENST00000513816 | RAPGEF2-212 | 0.001325547 | 3.037927 | up        |
| ENST00000600178 | ECH1-212    | 0.001325547 | -4.09493 | down      |
| ENST00000480454 | TRIM22-209  | 0.001325547 | 2.704678 | up        |
| ENST00000565440 | PKM-212     | 0.001325547 | -2.72849 | down      |
| ID             | Symbol | P-value   | log2FC  | Regulated |
|----------------|--------|-----------|---------|-----------|
| ENST00000555863| NEMF-207| 0.016201769 | -2.83837 | down      |
| ENST00000492144| EIF4A2-222| 0.016988381 | 3.027909 | up        |
| ENST00000508554| SNG2-202| 0.016442341 | 4.845588 | up        |
| ENST00000460378| EPB1A-208| 0.018492727 | 3.034999 | up        |
| ENST00000503459| ANAPC13-202| 0.017240099 | -4.01688 | down      |
| ENST00000572304| MAPK11-206| 0.018546851 | -3.0729  | down      |
| ENST00000475908| GLUL-208| 0.018651696 | -2.92766 | down      |
| ENST00000432675| EIF3D-205| 0.018967454 | -2.80598 | down      |
| ENST00000483654| UBXN1-203| 0.019178124 | 2.954689 | up        |
| ENST00000521112| RPL3-208| 0.019372092 | -2.7188  | down      |
| ENST00000564276| PKM-211| 0.019467707 | 2.308757 | up        |
| ENST00000475808| GLUL-208| 0.018546851 | -2.92766 | down      |
| ENST00000432675| EIF3D-205| 0.018967454 | -2.80598 | down      |
| ENST00000483654| UBXN1-203| 0.019178124 | 2.954689 | up        |
| ENST00000521112| RPL3-208| 0.019372092 | -2.7188  | down      |
| ENST00000564276| PKM-211| 0.019467707 | 2.308757 | up        |
| ENST00000475808| GLUL-208| 0.018546851 | -2.92766 | down      |
| ENST00000432675| EIF3D-205| 0.018967454 | -2.80598 | down      |
| ENST00000483654| UBXN1-203| 0.019178124 | 2.954689 | up        |
| ENST00000521112| RPL3-208| 0.019372092 | -2.7188  | down      |
| ENST00000564276| PKM-211| 0.019467707 | 2.308757 | up        |
| ENST00000475808| GLUL-208| 0.018546851 | -2.92766 | down      |
| ENST00000432675| EIF3D-205| 0.018967454 | -2.80598 | down      |
| ENST00000483654| UBXN1-203| 0.019178124 | 2.954689 | up        |
| ENST00000521112| RPL3-208| 0.019372092 | -2.7188  | down      |
| ENST00000564276| PKM-211| 0.019467707 | 2.308757 | up        |
| ENST00000475808| GLUL-208| 0.018546851 | -2.92766 | down      |
| ENST00000432675| EIF3D-205| 0.018967454 | -2.80598 | down      |
| ENST00000483654| UBXN1-203| 0.019178124 | 2.954689 | up        |
| ENST00000521112| RPL3-208| 0.019372092 | -2.7188  | down      |
| ENST00000564276| PKM-211| 0.019467707 | 2.308757 | up        |
| ENST00000475808| GLUL-208| 0.018546851 | -2.92766 | down      |
| ENST00000432675| EIF3D-205| 0.018967454 | -2.80598 | down      |
| ENST00000483654| UBXN1-203| 0.019178124 | 2.954689 | up        |
| ENST00000521112| RPL3-208| 0.019372092 | -2.7188  | down      |
Validation of Exosomal lncRNA Expression by qRT-PCR

To further verify the sequencing data, six differentially expressed exosomal lncRNAs, including one up-regulated (ENST00000525207) and five down-regulated (ENST00000495420, ENST00000488260, ENST00000505090, ENST00000472614, and ENST00000533796), were randomly selected to perform the qRT-PCR analysis (T1DM subjects N=30; age-, sex- matched Control subjects N=30). However, the results indicated that the expression levels of selected lncRNAs were similar between T1DM patients and control individuals (Figure 7).

**DISCUSSION**

Nowadays, it has been reached a consensus that T1DM is a multifactorial disease, and the precise pathogenic mechanisms are still obscure. Mounting evidence has suggested exosomes play an important role in the onset and development of T1DM (8, 22). However, research about the expression profiles of exosomal lncRNA in T1DM has not yet been reported. Here, we performed the transcriptome-wide expression patterns of plasma-derived exosomal lncRNAs in the T1DM using Illumina Hiseq platform, and further explore their function by bioinformatics analysis.

In the present study, 162 aberrantly expressed exosomal lncRNAs, including 77 up-regulated and 85 down-regulated, were identified. The lncRNA accounted for the most proportion of differentially expressed lncRNAs, which was in accordance with previous study (23). To further validate the expression level of identified exosomal lncRNA, six of them, one up-regulated and five down-regulated, were randomly selected to perform qRT-PCR analysis. However, no significant difference was detected between T1DM patients and control subjects.
The relatively limited sample size may contribute to the negative results more or less. Nevertheless, there were still 156 differentially expressed lncRNAs to be further test in future studies. We believe that some of these may have the potential to become novel biomarkers for T1DM given the fact that both exosome (22) and lncRNA (15) have been reported to be significantly associated with T1DM. It has been indicated that islet-derived exosomes can activate immune response and lead to autoimmune attack (24). Also, T lymphocyte-derived exosomes are associated with beta-cell dysfunction and death (25). Some studies also evaluated the diagnostic potential of exosomes in the context of T1DM. It has been demonstrated that human islet-derived exosomal RNAs were differentially expressed when exposed to proinflammatory cytokines (26). Another study investigated the plasma-derived exosomes and reported a distinct exosomes miRNAs signature in patients with long-duration T1DM (27). Some studies have also investigated the potential role of lncRNA in the T1DM pathogenesis. LncRNAs usually expressed in a cell-specific manner. Previous transcriptome profiling studies have identified more than 1000 islet-specific lncRNAs (28, 29). The dysfunction of lncRNAs may lead to autoimmune response and alter the progression of T1DM (30, 31). A recent whole genome RNA sequencing study in circulating leukocytes identified 393 differentially expressed lncRNAs, potentially providing novel targets for diagnosis and treatment of T1DM (32). Another study conducted a comparative analysis of the expression profiles of lncRNA by analyzing published microarray data set and proposed a specific 26-lncRNA signature, which could be used to effectively identify T1DM susceptible individuals (33). In addition, in vitro
experiment using MIN6 cells found that the expression of IncRNA was modified by cytokine treatment and overexpression of these IncRNA favored beta-cell apoptosis, indicating dysregulation of IncRNA contributes to the beta-cell failure during the development of T1DM (18). Furthermore, some specific IncRNAs have been reported to be implicated in beta-cell function and T1DM. It has been indicated that IncRNA MALAT1 could induce beta-cell dysfunction through inhibiting the expression of PDX-1 by reducing its H3 histone acetylation (34). The IncRNA Lnc13 could regulate the inflammation of pancreatic beta-cell by allele-specific stabilization of STAT1 mRNA (35). All the aforementioned studies suggested that both exosome and IncRNA were involved in the T1DM pathogenesis.

Next, to predict the potential biological functions of identified differentially expressed IncRNAs, we performed GO enrichment analysis and the KEGG pathway analysis. The terms such as activation of phospholipase D activity, neuronal cell body membrane, calcium sensitive guanylate cyclase activator activity, and metal ion binding were significantly enriched in the identified differentially exosomal IncRNAs. These terms were associated with diabetes or its complication to some extent. For instance, it has been shown that glycosylphosphatidylinositol-specific phospholipase D level were correlated to the insulin resistance of adipose tissue in obese subjects (36). Also, the expression of glycoprotein phospholipase D (GPLD1) was found to be increased in mouse models of T1DM (37, 38), and GPLD1 levels in autoimmune diabetes were higher than that in T2DM or healthy controls (39).

KEGG pathway analysis indicated that the differentially expressed IncRNAs were involved in oxidative phosphorylation, Parkinson’s disease (PD) and pathways in cancer. PD is also a multifactorial disease and both genetic and environmental factors contribute to the pathogenesis of this progressive neurodegenerative disease (40). The primary pathogenic mechanisms of PD remain unclear. However, some pathophysiological processes, such as mitochondrial dysfunction, oxidative stress, and chronic inflammation, are identified to be associated with PD (41). These processes are also involved in the onset and development of T1DM (42, 43), which suggested that PD and T1DM might share some common pathological features. Interestingly, another progressive neurodegeneration disease, Alzheimer’s disease (AD), has been proposed as “type 3 diabetes mellitus” because of the shared molecular and cellular characteristics with T1DM and T2DM (44).

LncRNAs were frequently precursor RNAs of miRNAs. We identified the precursor IncRNAs of miRNA through comparing miRNA sequence in miRbase database. Some identified miRNAs such as miR-21 (45) and miR-424 (46) has been implicated in the progression of T1DM. Therefore, the IncRNA combined miRNA might contribute to the T1DM collectively.

Both exosome and IncRNA have been implicated in the progression of T1DM. However, the exact role of exosomal IncRNA in T1DM lacks full investigation and research. The present study identified the expression profiles of exosomal IncRNA and laid foundation for further study in this field. There are some limitations of our study. First, the sample size was relatively small. Future study should include more samples to decrease the random errors. Second, we only selected six IncRNAs to validate their expression level by qRT-PCR and the sample size was relatively small. Further study should focus on more IncRNAs based on the sequencing results and assess the biomarker potential of exosomal IncRNAs in a larger sample set. Third, we didn’t investigate the function of exosomal IncRNAs and some in vitro or in vivo study are required in future study.

In conclusion, this study identified the characteristics of the plasma-derived exosomal IncRNA transcriptome of T1DM for...
the first time and threw insights into the biomarker potential and pathogenic factor of exosomal IncRNA in T1DM.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are publicly available. This data can be found here: [https://db.cngb.org/cnsa/accession number CNP0002574].

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by the Ethics Committee of the Second Xiangya Hospital. The patients/participants provided their written informed consent to participate in this study.

REFERENCES
1. DiMeglio LA, Evans-Molina C, Oram RA. Type 1 Diabetes. Lancet (2018) 391(10138):2449–62. doi: 10.1016/S0140-6736(18)31320-5
2. Xie Z, Chang C, Zhou Z. Molecular Mechanisms in Autoimmune Type 1 Diabetes: A Critical Review. Clin Rev Allergy Immunol (2014) 47(2):174–92. doi: 10.1007/s12126-014-8422-2
3. Luo S, Deng M, Xie Z, Li X, Huang G, Zhou Z. Circulating Circular RNAs Profiles Associated With Type 1 Diabetes. Diabetes Metab Res Rev (2021) 37(3):e3394. doi: 10.1002/dmrr.3394
4. Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, et al. Incidence Trends of Type 1 and Type 2 Diabetes Among Youths, 2002-2012. N Engl J Med (2017) 376(15):1419–29. doi: 10.1056/NEJMoa1610187
5. Pang H, Luo S, Huang G, Xia Y, Xie Z, Zhou Z. Advances in Knowledge of Candidate Genes Acting at the Beta-Cell Level in the Pathogenesis of T1DM. Front Endocrinol (Lausanne) (2020) 11:119. doi: 10.3389/fendo.2020.00119
6. Wang Z, Xie Z, Lu Q, Chang C, Zhou Z. Beyond Genetics: What Causes Type 1 Diabetes. Clin Rev Allergy Immunol (2017) 52(2):273–86. doi: 10.1007/s12016-016-8592-1
7. Xia Y, Xie Z, Huang G, Zhou Z. Incidence and Trend of Type 1 Diabetes and the Underlying Environmental Determinants. Diabetes Metab Res Rev (2019) 35(1):e3075. doi: 10.1002/dmrr.3075
8. Pang H, Luo S, Xiao Y, Xia Y, Li X, Huang G, et al. Emerging Roles of Exosomes in T1DM. Front Immunol (2020) 11:593348. doi: 10.3389/fimmu.2020.593348
9. Thery C, Zitvogel L, Amigorena S. Exosomes: Composition, Biogenesis and Function. Nat Rev Immunol (2002) 2(8):569–79. doi: 10.1038/nri855
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-Mediated Transfer of mRNAs and microRNAs Is a Novel Mechanism of Genetic Exchange Between Cells. Nat Cell Biol (2007) 9(6):654–9. doi: 10.1038/nclcb1596
11. Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. BioScience (2015) 65(8):783–97. doi: 10.1093/biosci/biv084
12. Lodde V, Murgia G, Simula ER, Steri M, Floris M, Idda ML. Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases. Biomolecules (2020) 10(7). doi: 10.3390/biom10071044
13. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, et al. Chromatin Signature Reveals Over a Thousand Highly Conserved Large Non-Coding RNAs in Mammals. Nature (2009) 458(7235):223–7. doi: 10.1038/nature07672
14. Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many Human Large Intergenic Noncoding RNAs Associate With Chromatin-Modifying Complexes and Affect Gene Expression. Proc Natl Acad Sci USA (2009) 106(28):11667–72. doi: 10.1073/pnas.0904715106
15. Mizzau AH, Kaur S, Poictiot F. Long non-Coding RNAs as Novel Players in Beta Cell Function and Type 1 Diabetes. Hum Genomics (2017) 11(1):17. doi: 10.1186/s40246-017-0113-7
16. Knoll M, Lodish HF, Sun L. Long non-Coding RNAs as Regulators of the Endocrine System. Nat Rev Endocrinol (2015) 11(3):151–60. doi: 10.1038/nrendo.2014.229
17. Eliasson L, Euguilera JL. Role of Non-Coding RNAs in Pancreatic Beta-Cell Development and Physiology. Acta Physiol (Oxf) (2014) 211(2):273–84. doi: 10.1111/apha.12285
18. Motterle A, Gattesco S, Caille D, Media P, Regazzi R. Involvement of Long non-Coding RNAs in Beta Cell Failure at the Onset of Type 1 Diabetes in NOD Mice. Diabetologia (2015) 58(8):1827–35. doi: 10.1007/s00125-015-3641-5
19. Mao X, Cai T, Olyarchuk JG, Wei L. Automated Genome Annotation and Pathway Identification Using the KEGG Orthology (KO) as a Controlled Vocabulary. Bioinformatics (2005) 21(19):3787–93. doi: 10.1093/bioinformatics/bti430
20. Ma H, Hao Y, Dong X, Gong Q, Chen J, Zhang J, et al. Molecular Mechanisms and Function Prediction of Long Noncoding RNA. ScientificWorldJournal (2012) 2012:541786. doi: 10.1105/2012/541786
21. Sun M, Kraus WL. From Discovery to Function: The Expanding Roles of Long Non-Coding RNAs in Physiology and Disease. Endocr Rev (2015) 36(1):25–64. doi: 10.1210/er.2014-1034
22. Chang W, Wang J. Exosomes and Their Noncoding RNA Cargo Are Emerging as New Modulators for Diabetes Mellitus. Cells (2019) 8(6). doi: 10.3390/cells0806053
23. Ransohoff JD, Wei Y, Khavari PA. The Functions and Unique Features of Long Intergenic non-Coding RNA. Nat Rev Mol Cell Biol (2018) 19(3):143–57. doi: 10.1038/nrm.2017.104
24. Dai YD, Sheng H, Dias P, Jubayer Rahman M, Bashratyan R, Rehn D, et al. Autoimmune Responses to Exosomes and Candidate Antigens Contribute to Type 1 Diabetes in Non-Obese Diabetic Mice. Curr Diab Rep (2017) 17(12):130. doi: 10.1007/s11922-017-0962-4
25. Guay C, Kruit JK, Rome S, Muna Y, Mulder NL, Jurdzinski A, et al. Exosomes as a Novel Therapeutic Strategy for Cystic Fibrosis. Cell Metab (2019) 29(2):348–61 e6. doi: 10.1016/j.cmet.2018.09.011
26. Krishnan P, Syed F, Jayan Kang N, Mirmira RG, Evans-Molina C. Profiling of RNAs From Human Islet-Derived Exosomes in a Model of Type 1 Diabetes. Int J Mol Sci (2019) 20(23). doi: 10.3390/ijms20235903
27. Garcia-Contreras M, Shah SH, Tamayo A, Robbins PD, Golberg RB, Mendez AJ, et al. Plasma-Derived Exosome Characterization Reveals a Distinct

AUTHOR CONTRIBUTIONS
ZZ, ZX, and HP conceived and designed the experiments. HP, WF, JLi, YW, SL, JLin, GH, and XL collected samples. HP, XS, and WF performed the experiments and analyzed the data. HP wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by the National Natural Science Foundation of China (grant numbers 82070813, 81873864, 81400783), the National Key R&D Program of China (grant numbers 2016YFC1305000, 2016YFC1305001, 2018YFC1315603), and the Hunan Province Natural Science Foundation of China (grant numbers 2018JJ2573, 2020JJ2053).
microRNA Signature in Long Duration Type 1 Diabetes. Sci Rep (2017) 7(1):5996. doi: 10.1038/s41598-017-05787-y
28. Ku GM, Kim H, Vaugha R, Hangsou NG, Myung Oh C, German MS, et al. Research Resource: RNA-Seq Reveals Unique Features of the Pancreatic Beta-Cell Transcriptome. Mol Endocrinol (2012) 26(10):1783–92. doi: 10.1210/me.2012-1176
29. Moran I, Akerman I, van de Bunt M, Xie R, Benazra M, Nannmno T, et al. Human Beta Cell Transcriptome Analysis Uncovers lncRNAs That are Tissue-Specific, Dynamically Regulated, and Abnormally Expressed in Type 2 Diabetes. Cell Metab (2012) 16(4):435–48. doi: 10.1016/j.cmet.2012.08.010
30. Chen J, Ao L, Yang J. Long Non-Coding RNAs in Diseases Related to Inflammation and Immunity. Ann Transl Med (2019) 7(18):494. doi: 10.21037/atm.2019.08.37
31. Xu F, Jin L, Jin Y, Nie Z, Zheng H. Long Noncoding RNAs in Autoimmune Diseases. J BioMed Mater Res A (2019) 107(2):468–75. doi: 10.1002/jbmm.a.36562
32. Liu Y, Du X, Cui J, Li C, Guo M, Lv J, et al. A Genome-Wide Analysis of Long Noncoding RNAs in Circulating Leukocytes and Their Differential Expression in Type 1 Diabetes Patients. J Diabetes Res (2020) 2020:9010314. doi: 10.1155/2020/9010314
33. Geng G, Zhang Z, Cheng L. Identification of a Multi-Long Noncoding RNA Signature for the Diagnosis of Type 1 Diabetes Mellitus. Front Bioeng Biotechnol (2020) 8:533. doi: 10.3389/fbioe.2020.00533
34. Ding H, Wang F, Shi X, Ma H, Du Y, Hou L, et al. lncRNA MALAT1 Induces the Dysfunction of Beta Cells via Reducing the Histone Acetylation of the PDX-1 Promoter in Type 1 Diabetes. Exp Mol Pathol (2020) 114:104432. doi: 10.1016/j.yexmp.2020.104432
35. Gonzalez-Moro I, Olazagaita-Garmendia A, Colli ML, Cobo-Vuilleumier N, Postler TS, Manselli L, et al. The T1D-Associated lncRNA Lnc13 Modulates Human Pancreatic Beta Cell Inflammation by Allele-Specific Stabilization of STAT1 mRNA. Proc Natl Acad Sci USA (2020) 117(16):9022–31. doi: 10.1073/pnas.1914353117
36. Zhang K, Zhu H, Wang L, Yang H, Pan H, Gong F. Serum Glycine4 and Glycosylphosphatidylinositol-Specific Phospholipase D Levels are Associated With Adipose Tissue Insulin Resistance in Obese Subjects With Different Glucose Metabolism Status. J Endocrinol Invest (2021) 44(4):781–90. doi: 10.1007/s40618-020-01372-9
37. Deeg MA, Bowen RF, Williams MD, Olson LK, Kirk EA, LeBoeuf RC. Increased Expression of GPI-Specific Phospholipase D in Mouse Models of Type 1 Diabetes. Am J Physiol Endocrinol Metab (2001) 281(1):E147–54. doi: 10.1152/ajpendo.2001.281.1.E147
38. Schofield JN, Stephens JW, Hurel SJ, Bell KM, deSouza JB, Rademacher TW. Insulin Reduces Serum Glycosylphosphatidylinositol Phospholipase D Levels in Human Type I Diabetic Patients and Streptozotocin Diabetic Rats. Mol Genet Metab (2002) 75(2):154–61. doi: 10.1006/mgen.2001.3287
39. Qin W, Liang YZ, Qin BY, Zhang J, Xia N. The Clinical Significance of Glycoprotein Phospholipase D Levels in Distinguishing Early Stage Latent Autoimmune Diabetes in Adults and Type 2 Diabetes. PloS One (2016) 11(6):e0156959. doi: 10.1371/journal.pone.0156959
40. Samii A, Nutt JG, Ransom BR. Parkinson’s Disease. Lancet (2004) 363(9423):1783–93. doi: 10.1016/S0140-6736(04)63050-8
41. Hayes MT. Parkinson’s Disease and Parkinsonism. Am J Med (2019) 132(7):802–7. doi: 10.1016/j.amjmed.2019.03.001
42. Chen J, Stimpson SE, Fernandez-Bueno GA, Mathews CE. Mitochondrial Reactive Oxygen Species and Type 1 Diabetes. Antioxid Redox Signal (2018) 29(14):1361–72. doi: 10.1089/ars.2017.7346
43. Eizirik DL, Colli ML, Ortiz F. The Role of Inflammation in Insulitis and Beta-Cell Loss in Type 1 Diabetes. Nat Rev Endocrinol (2009) 5(4):219–26. doi: 10.1038/nrendo.2009.21
44. Kandimalla R, Thrirumala V, Reddy PH. Is Alzheimer’s Disease a Type 3 Diabetes? A Critical Appraisal. Biochim Biophys Acta Mol Basis Dis (2017) 1863(5):1078–89. doi: 10.1016/j.bbamed.2016.08.018
45. Mostafaezian M, Azhir Z, Dehghanian F, Hojati Z. Expression Pattern of microRNAs, miR-21, miR-155 and miR-338 in Patients With Type 1 Diabetes. Arch Med Res (2019) 50(3):79–85. doi: 10.1016/j.arcmed.2019.07.002
46. Kong Q, Guo X, Guo Z, Su T. Urinary Exosome miR-424 and miR-218 as Biomarkers for Type 1 Diabetes in Children. Clin Lab (2019) 65(6). doi: 10.7754/Clin.Lab.2018.180921

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pang, Fan, Shi, Li, Wang, Luo, Lin, Huang, Li, Xie and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.